(VIANEWS) – Shares of INVENTIVA (CAC 40: IVA.PA) slid by a staggering 34.2% in 21 sessions from €4.6 to €3.03 at 11:55 EST on Tuesday, after four successive sessions in a row of losses. CAC 40 is rising 0.54% to €7,385.44, after five sequential sessions in a row of gains.
About INVENTIVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Earnings Per Share
As for profitability, INVENTIVA has a trailing twelve months EPS of €-0.992.
Volume
Today’s last reported volume for INVENTIVA is 24542 which is 95.77% above its average volume of 25800.
More news about INVENTIVA (IVA.PA).
